Cancer Diagnostics Market: as pan-tumor consolidation accelerates through Abbott's pending acquisition of Exact Sciences, comprehensive genomic profiling and blood-based screening are converging on the same diagnostic pathway, so a single validated platform now spans screening through treatment selection, and scale increasingly determines which diagnostics companies can fund the next generation of pan-cancer testing.

The global cancer diagnostics market size was USD 28.6 Billion in 2025 and is expected to register a revenue CAGR of 9.8% during the forecast period.Market revenue growth is driven by factors such as accelerating pan-tumor consolidation among diagnostics incumbents, expanding FDA approval of blood-based and comprehensive genomic profiling tests, and the structural rise in global cancer incidence.The first driving factor is accelerating pan-tumor consolidation among diagnostics incumbents seeking immediate scale in fast-growing cancer screening and precision oncology segments.A definitive agreement announced in November 2025 valued the target company's equity at approximately USD 21 Billion, reflecting how established diagnostics companies are choosing acquisition over organic build-out to enter high-growth pan-cancer testing categories.The second driving factor is expanding FDA approval of blood-based screening and comprehensive genomic profiling tests that broaden non-invasive testing access.More than 60% of newly approved pan-cancer diagnostic claims since 2025 have come through the Breakthrough Device or companion diagnostic pathway rather than a traditional standalone submission.The third driving factor is the structural rise in global cancer incidence documented by international cancer registries.The International Agency for Research on Cancer reported close to 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with annual new cases projected to reach 35 million by 2050.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single comprehensive genomic profiling platform widens its addressable revenue every time it adds a new companion diagnostic claim on the same underlying assay, without the developer having to build and validate a new test from zero.Once a pan-cancer genomic profiling platform earns its first companion diagnostic claim, each additional claim tied to a new targeted therapy adds incremental revenue on the same installed assay and laboratory relationship, so platform revenue compounds as the therapy-matching claim list grows around the original test.As a result, demand and revenue share are concentrating around platforms that combine the broadest companion diagnostic claim set with blood-based screening reach, that hold both treatment-selection and early-detection use cases, and the forecast tilts toward these dual-purpose platforms rather than single-indication tests.For instance, in August 2025, Thermo Fisher Scientific, United States, received FDA approval for its Oncomine Dx Target Test as a companion diagnostic for HERNEXEOS, a newly approved lung cancer therapy, extending the same underlying NGS assay's approved claim set without a new platform validation.These are some of the key factors driving revenue growth of the market.

Because Medicare pricing for individual comprehensive genomic profiling tests has shown material year-over-year volatility even for established, clinically validated assays, diagnostics manufacturers face ongoing reimbursement rate uncertainty that complicates multi-year commercial planning.

International access disparity is a second constraint, because only 39% of countries participating in a global universal health coverage survey adequately financed basic cancer management services, so high-income markets with mature comprehensive genomic profiling reimbursement pull structurally ahead of lower-income countries still building foundational cancer diagnostic infrastructure.

Large-scale pan-tumor consolidation activity is a third constraint, since integration execution risk and antitrust review timelines can delay the commercial synergies that major diagnostics mergers are announced to deliver, extending the period before combined entities realise the scale benefits used to justify the transaction.

These factors substantially limit cancer diagnostics market growth over the forecast period.

The clearest driver of demand is large-scale pan-tumor consolidation among established diagnostics incumbents. Building a pan-cancer screening and precision oncology portfolio organically requires years of clinical validation and guideline adoption, and acquiring an established franchise compresses that timeline to a single transaction, so incumbents with balance sheet capacity are increasingly choosing to buy rather than build. The Abbott-Exact Sciences transaction alone creates a new Oncology Diagnostics sub-segment spanning colorectal cancer screening, breast cancer recurrence-risk testing, and multi-cancer early detection within a single combined entity. A definitive agreement was announced in November 2025 under which Exact Sciences shareholders will receive USD 105 per common share in cash, representing a total equity value of approximately USD 21 Billion, with closing expected in the second quarter of 2026 subject to shareholder and antitrust approval. The effect on the market is that commercial scale, not just clinical validation, is becoming a prerequisite for competing in pan-cancer screening and precision oncology diagnostics. These are some of the key factors driving revenue growth of the market.

The second driver is FDA approval momentum for blood-based screening and comprehensive genomic profiling assays. A blood-based or comprehensive genomic test only converts into broad clinical use once it clears both FDA approval and Medicare coverage, and multiple assays cleared that combined bar in rapid succession through 2025, so non-invasive testing volume is scaling faster than in prior years. Guardant Health's Shield blood test has now screened nearly 100,000 patients since its original approval, and its multi-cancer detection expansion has been selected for the National Cancer Institute's Vanguard Study evaluating emerging multi-cancer detection technology. In June 2025, Guardant Health, United States, received FDA Breakthrough Device designation for its Shield multi-cancer detection test, and in August 2025 Thermo Fisher Scientific, United States, received FDA approval for its Oncomine Dx Target Test as a companion diagnostic for a newly approved non-small cell lung cancer therapy. The effect on the market is that non-invasive testing is expanding from single-cancer screening into multi-cancer detection and treatment-selection use cases on the same regulatory and reimbursement infrastructure. These are some of the key factors driving revenue growth of the market.

“Guardant Health's Shield test has now screened nearly 100,000 patients since FDA approval, and its multi-cancer detection expansion has already earned Breakthrough Device designation.”

The third driver is the structural, long-term rise in global cancer incidence documented by international cancer registries. Diagnostic testing demand only grows sustainably if the underlying disease burden is genuinely rising rather than plateauing, and IARC's GLOBOCAN projections confirm sustained growth through mid-century, so testing capacity investment reflects a multi-decade demand curve rather than a short-term screening cycle. The International Agency for Research on Cancer reported close to 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with annual new cases projected to reach 35 million by 2050. In 2025, Roche launched its next-generation SBX sequencing platform to enhance clinical laboratory sequencing accuracy and scalability, positioning the company's diagnostics division, which generated approximately USD 15.7 Billion in fiscal 2024 revenue, for the rising testing volume the incidence data implies. The effect on the market is that diagnostic testing capacity investment is being sized against a multi-decade rising incidence curve rather than current-year demand alone. These are some of the key factors driving revenue growth of the market.

However, the cancer diagnostics market faces severe adoption constraints from international reimbursement heterogeneity and pan-tumor consolidation integration risk.

Because Medicare and international payer pricing for comprehensive genomic profiling and blood-based screening tests shows material year-over-year volatility even for established, clinically validated assays, diagnostics manufacturers must navigate ongoing reimbursement uncertainty that complicates multi-year commercial planning.

International access disparity compounds this, because only 39% of countries participating in a global universal health coverage survey adequately financed basic cancer management services, so the access gap between high-income markets with mature comprehensive genomic profiling reimbursement and lower-income countries widens even as testing innovation accelerates.

Large-scale pan-tumor consolidation activity is the third constraint, since integration execution risk and antitrust review timelines, informed by prior FTC-mandated divestiture experience in diagnostics deals, can delay the commercial synergies that transactions like Abbott-Exact Sciences are announced to deliver, so realised scale benefits typically lag announced deal value by several quarters.

These factors substantially limit cancer diagnostics market growth over the forecast period.

Based on cancer type, the global cancer diagnostics market is segmented into colorectal cancer, lung cancer, breast cancer, prostate cancer, and other solid tumors and hematologic malignancies. Colorectal cancer accounts for a leading cancer-type revenue share, anchored by the established Cologuard stool-based screening franchise and the FDA-approved Shield blood test. Thermo Fisher Scientific's Oncomine Dx Target Test companion diagnostic approvals target non-small cell lung cancer, the leading cause of cancer death in both the Japanese and US markets, illustrating how lung cancer diagnostic innovation increasingly depends on pharma-diagnostics partnership models. The liquid biopsy and blood-based screening sub-segment, applicable across colorectal, lung, breast, and other solid tumor types, is expected to register a rapid revenue growth rate over the forecast period as blood-based tests increasingly substitute for or complement traditional tissue biopsy.

Based on regional analysis, the cancer diagnostics market in North America accounted for the largest revenue share in 2025, at approximately 41% of global market revenue. The United States drives the regional position through Abbott's pending USD 21 Billion acquisition of Exact Sciences consolidating commercial scale in cancer screening and precision oncology, alongside 2025 FDA approvals for Guardant Health's Shield multi-cancer detection designation and Thermo Fisher's Oncomine Dx Target Test companion diagnostic. Roche's diversified diagnostics portfolio generated approximately USD 15.7 Billion in fiscal year 2024 revenue, with the company's 2025 launch of its next-generation SBX sequencing platform aimed at major US clinical laboratory customers. The concentration of FDA approvals and pending consolidation activity in the United States also means new pan-cancer diagnostic products are often launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate in the global cancer diagnostics market over the forecast period.

Germany, the United Kingdom, and France represent the three largest national cancer diagnostics markets in Europe. Pan-cancer comprehensive genomic profiling assays received CE marking and commercial availability in the European Union in 2022, two years ahead of equivalent US FDA approval, illustrating how the EU IVDR regulatory pathway has in some cases enabled earlier European market access. The result is steady rather than rapid growth, shaped more by national reimbursement infrastructure than by the underlying regulatory access advantage Europe has held on comprehensive genomic profiling.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global cancer diagnostics market over the forecast period.

China, Japan, and South Korea represent the three largest national cancer diagnostics markets within the region. Almost one half of all global cancer cases and the majority of cancer deaths in 2022 occurred in Asia, where 59.2% of the world's population resides, establishing the region as both the largest absolute cancer burden and the largest addressable testing population globally. Cross-industry pharma-diagnostics collaborations targeting non-small cell lung cancer, the leading cause of cancer death in major Asian markets, illustrate how international partnerships are extending comprehensive genomic profiling access into markets that have historically lagged North American adoption, leaving more structural room for growth than in the already-established US market.

The market in Latin America is expected to register a moderate revenue growth rate in the global cancer diagnostics market over the forecast period.

Brazil and Mexico represent the two largest national cancer diagnostics markets in the region, with access to comprehensive genomic profiling and liquid biopsy testing concentrated at a small number of private and academic oncology referral centres in São Paulo, Mexico City, and Buenos Aires. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have raised freight and import costs for molecular diagnostics reagent kits and sequencing instrument components entering Brazilian and Mexican distribution channels, a disruption that has run through 2026 and constrains public-sector adoption beyond the largest private referral centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global cancer diagnostics market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for comprehensive cancer diagnostic and treatment programmes, anchored by King Faisal Specialist Hospital and Research Centre in Riyadh, while the wider Gulf and North African sub-regions are still building the basic molecular diagnostic infrastructure comprehensive genomic profiling requires from scratch.